PMOS in Canada: What the PCOS Rename Means for Canadian Patients (2026)

PCOS/PMOS Prevalence in Canada

PMOS affects an estimated 10–13% of women aged 15–49 in Canada, consistent with global prevalence figures from the Endocrine Society (2026) and WHO. Based on Statistics Canada data on the female population aged 15–49 (approximately 10–11 million women), this translates to roughly 1.0–1.4 million Canadians living with PMOS at any given time — making it one of the most common endocrine conditions in the country.

Despite this prevalence, diagnostic delay remains a significant problem in Canada, consistent with the global average of 2–3 years from symptom onset to diagnosis (ESHRE 2023). Contributing factors in the Canadian context include:

• GP gatekeeping variability: Specialist wait times across provinces mean that initial assessment and management in primary care is essential — but awareness of PMOS diagnostic criteria (Rotterdam 2003, updated ESHRE 2023) varies significantly among GPs.
• Lean PMOS under-recognition: The 20–30% of women with PMOS who are at normal body weight are frequently told they “don't look like they have PCOS.” The PMOS rename's de-emphasis of the “polycystic” appearance may help address this.
• Francophone access gaps: French-language resources on PMOS have historically been limited compared to English resources, creating a disparity for Quebec and Acadian patients.

The PMOS rename, with its emphasis on metabolic and endocrine dimensions, is expected to improve how Canadian GPs assess and monitor insulin resistance, cardiovascular risk, and mental health in patients with PMOS — reducing the condition's de facto treatment as a purely reproductive concern.

SOGC (Society of Obstetricians and Gynaecologists of Canada) Position

The Society of Obstetricians and Gynaecologists of Canada (SOGC) is the primary national specialty society for obstetrics and gynaecology in Canada. The SOGC publishes clinical practice guidelines (CPGs) that are widely used by Canadian GPs, obstetricians, and gynaecologists in day-to-day practice.

The SOGC has not yet issued a formal position statement on the PMOS rename as of May 2026. Based on the pattern of adoption by equivalent bodies in the UK (RCOG) and Australia (RANZCOG) — with response statements expected in Q3–Q4 2026 — the SOGC is anticipated to publish guidance in the Q4 2026 to Q1 2027 timeframe.

Clinical practice implications: SOGC's existing CPG on PCOS, aligned with the Monash 2023 guideline, already reflects best-practice PMOS management. Key Canadian clinical practice points:

• Letrozole first-line for ovulation induction — supported by SOGC in alignment with Monash 2023 and the Legro 2014 NEJM data.
• Comprehensive metabolic workup at diagnosis — fasting glucose, HbA1c, full lipid panel, and HOMA-IR for all newly diagnosed PMOS patients, regardless of BMI.
• Psychological screening — SOGC recommends assessment for depression and anxiety at initial diagnosis, consistent with the 4× and 3× elevated prevalence data (Barry et al., 2011).

Provincial Coverage Variations

Canada's healthcare system is administered provincially, which creates meaningful variation in access to PMOS care and fertility treatment across the country.

Ontario (OHIP)

OHIP covers standard GP visits, specialist referrals, and laboratory tests for PMOS diagnosis and management. Ontario fertility coverage is more extensive than most provinces: since 2015, OHIP has covered one IVF cycle per patient lifetime under specific criteria, including anovulatory infertility caused by PMOS. Letrozole for ovulation induction is covered when prescribed by a specialist. The Assisted Reproduction Program (ARP) funding applies to Ontario residents meeting eligibility criteria at designated fertility centres.

Quebec (RAMQ)

Quebec's RAMQ offers among the most comprehensive fertility coverage in Canada. Until 2015, RAMQ funded three complete IVF cycles; the current program provides a refundable tax credit (up to $20,000 per treatment) for medically necessary fertility treatments including IVF and IUI. PMOS-related anovulatory infertility qualifies for this coverage. Quebec also has strong French-language medical resources, and the FMOQ (Fédération des médecins omnipraticiens du Québec) provides GP training materials that include PCOS/PMOS management protocols in French.

British Columbia (MSP)

BC's Medical Services Plan covers diagnostic and management services for PMOS at the GP and specialist level. However, BC does not cover IVF through MSP — fertility treatments requiring IVF or ICSI are paid out-of-pocket or through private insurance. Letrozole for ovulation induction and metformin for insulin resistance are covered on the BC PharmaCare formulary when prescribed for relevant indications. BC's Reproductive Care Program provides guidelines for fertility specialists working with PMOS patients.

For Francophone Quebec Patients

Quebec has a distinctive position in the Canadian PMOS landscape: as the country's primarily Francophone province, Quebec patients benefit from a growing ecosystem of French-language resources — and from strong provincial support for fertility treatment.

In French, the new name for PCOS is SMOP — Syndrome Métabolique Ovarien Polyendocrinien, the direct equivalent of PMOS. The sister site sopk-smop.fr/smop/ provides comprehensive French-language content on SMOP/PMOS — covering symptoms, diagnostic criteria, treatments, and patient tools. While this site is based in France, the clinical content is directly applicable to Quebec patients (same diagnostic criteria, same treatments, same evidence base). The French equivalent of the Endocrine Society position (Société Francophone d'Endocrinologie, SFE) is also expected to adopt the SMOP terminology formally in 2026.

Quebec-specific resources in French:

• FMOQ (Fédération des médecins omnipraticiens du Québec): omnipraticien.ca — GP-facing resources including SOPK/SMOP management protocols in French.
• AMSGOQ (Association des médecins spécialistes en gynécologie-obstétrique du Québec): amsgoq.com — specialist society resources for Quebec gynaecologists.
• Clé de santé: cledesante.com — a French-language patient health portal with SOPK/PMOS content for Quebec and Francophone Canadian patients.

For Quebec patients seeing a French-speaking GP or specialist, it is helpful to use the SOPK (Syndrome des ovaires polykystiques) terminology alongside SMOP when discussing the condition, as the rename awareness timeline in Francophone practice mirrors the general Canadian trajectory of late 2026 to 2027.

Indigenous and First Nations Women

PMOS disproportionately affects Indigenous, First Nations, and Métis women in Canada. Population-based data from Indigenous health surveys and provincial epidemiology studies indicate higher rates of PMOS and its metabolic comorbidities — particularly insulin resistance, type 2 diabetes, and metabolic syndrome — among Indigenous women compared to the general Canadian population. This reflects the compounding effects of systemic health inequities, food insecurity, and historical trauma on metabolic and reproductive health.

Access to culturally safe care remains a significant challenge. Indigenous women with PMOS face additional barriers including geographic remoteness, mistrust of the medical system rooted in historical harms (including forced sterilization), and a lack of culturally safe reproductive health services. The PMOS rename, while clinically neutral, occurs within a broader healthcare system that has historically underserved Indigenous women.

Relevant resources and initiatives for Indigenous women with PMOS in Canada:

• National Collaborating Centre for Indigenous Health (NCCIH): nccih.ca — resources on Indigenous women's health equity and reproductive health.
• First Nations Health Authority (BC): fnha.ca/wellness — BC-specific resources for First Nations women's health, including chronic disease management.
• Indigenous health liaisons: Many urban Indigenous health centres offer liaison services to help navigate specialist referrals and provincial coverage entitlements.
• Jordan's Principle: Eligible First Nations children and youth with PMOS onset in adolescence may access services, products, and supports through Jordan's Principle — a child-first policy that funds health gaps not covered by provincial programs.

Advocates and health equity researchers have called for the integration of Indigenous-specific prevalence data into national PMOS guidelines and for culturally appropriate patient education resources — work that remains ongoing within the Canadian PMOS research community.

Frequently Asked Questions — PMOS in Canada

Does the PMOS rename affect my provincial health coverage in Canada?

No. Provincial health coverage in Canada uses ICD-10 code E28.2 for PCOS/PMOS, which remains unchanged during the 3-year transition period. Your provincial health card coverage for GP visits, specialist referrals, and covered lab tests is unaffected by the terminology change.

What does SOGC recommend for PMOS management?

The Society of Obstetricians and Gynaecologists of Canada (SOGC) aligns with the Monash International PCOS Guideline 2023 and the ESHRE 2023 framework. Key SOGC-aligned recommendations include letrozole as first-line for ovulation induction, comprehensive metabolic screening at diagnosis (fasting glucose, HbA1c, lipids), and psychological wellbeing assessment for all patients. SOGC is expected to issue guidance on the PMOS terminology transition in 2026.

Is there a French-language PMOS resource for Quebec patients?

Yes. In France and Quebec, the French equivalent of PMOS is SMOP — Syndrome Métabolique Ovarien Polyendocrinien. The sister site sopk-smop.fr provides comprehensive French-language resources on SMOP/PMOS. Quebec-specific resources are also available through the Fédération des médecins omnipraticiens du Québec (FMOQ) and the Association des médecins spécialistes en gynécologie-obstétrique du Québec (AMSGOQ).

How do I find a PMOS specialist in my province?

Your family physician or GP can refer you to an endocrinologist or reproductive endocrinologist/fertility specialist depending on your primary concern. To find specialists: ask your GP for a direct referral (provincially covered), contact your provincial college of physicians for a specialist directory, or use platforms like Rate MDs (ratemds.com) filtered by specialty. Wait times vary significantly by province — Ontario and BC typically have longer waits; asking your GP for an urgent referral if symptoms are significantly impacting quality of life can help.

Does PMOS affect my eligibility for provincial fertility coverage?

Fertility coverage varies by province. Ontario (OHIP) covers one IVF cycle under specific criteria including anovulatory infertility — which applies to PMOS. Quebec (RAMQ) covers three IVF cycles plus unlimited IUI. BC's MSP does not cover IVF but covers diagnostic tests. The PMOS rename does not change these eligibility criteria. Check your provincial health authority website or speak to a fertility specialist for current criteria in your province.